Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial

MLA

Kaiyan Chen, et al. “Sintilimab plus Anlotinib as Second‐ or Third‐line Therapy in Metastatic Non‐small Cell Lung Cancer with Uncommon Epidermal Growth Factor Receptor Mutations: A Prospective, Single‐arm, Phase II Trial.” Cancer Medicine, vol. 12, no. 19, Oct. 2023, pp. 19460–70. EBSCOhost, https://doi.org/10.1002/cam4.6548.

APA

Kaiyan Chen, Yanjun Xu, Zhiyu Huang, Xiaoqing Yu, Wei Hong, Hui Li, Xiaoling Xu, Hongyang Lu, Fajun Xie, Jun Chen, Youzu Xu, & Yun Fan. (2023). Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial. Cancer Medicine, 12(19), 19460–19470. https://doi.org/10.1002/cam4.6548

Chicago

Kaiyan Chen, Yanjun Xu, Zhiyu Huang, Xiaoqing Yu, Wei Hong, Hui Li, Xiaoling Xu, et al. 2023. “Sintilimab plus Anlotinib as Second‐ or Third‐line Therapy in Metastatic Non‐small Cell Lung Cancer with Uncommon Epidermal Growth Factor Receptor Mutations: A Prospective, Single‐arm, Phase II Trial.” Cancer Medicine 12 (19): 19460–70. doi:10.1002/cam4.6548.